{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:49:50Z","timestamp":1772016590284,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005317","name":"Kermanshah University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.arcmed.2020.04.018","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T23:10:21Z","timestamp":1588115421000},"page":"577-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered\/Approved Clinical Trial?"],"prefix":"10.1016","volume":"51","author":[{"given":"Babak","family":"Sayad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Sobhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Khodarahmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.04.018_bib1","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arcmed.2020.04.018_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2020.04.018_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.arcmed.2020.03.011","article-title":"Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?","volume":"51","author":"Gracia-Ramos","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2020.04.018_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/molpharm.120.000014","article-title":"Does COVID19 infect the brain? If so, smokers might be at a higher risk","volume":"97","author":"Kabbani","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.arcmed.2020.04.018_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.04.018_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.arcmed.2020.03.005","article-title":"Practical Strategies Against the Novel Coronavirus and COVID-19\u2014the Imminent Global Threat","volume":"51","author":"Rahimi","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2020.04.018_bib7","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase","author":"Chien","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.arcmed.2020.04.018_bib8","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase","author":"Ju","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.arcmed.2020.04.018_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2020.04.018_bib10","doi-asserted-by":"crossref","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.arcmed.2020.04.018_bib11","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1586\/14787210.2013.855126","article-title":"Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection","volume":"11","author":"Rodr\u00edguez-Torres","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.arcmed.2020.04.018_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in\u00a0vitro drug product dissolution and in\u00a0vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.arcmed.2020.04.018_bib13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/17460441.2015.1094051","article-title":"The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C","volume":"10","author":"Gentile","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.arcmed.2020.04.018_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3851\/IMP2733","article-title":"Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938","volume":"19","author":"Guedj","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.arcmed.2020.04.018_bib15","article-title":"No Resistance Detected in four Phase 3 Clinical Studies in HCV Genotype 1-6 of Sofosbuvir+ Ribavirin with or without Peginterferon: 1843","volume":"58","author":"Svarovskaia","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2020.04.018_bib16","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.04.018_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.04.018_bib18","doi-asserted-by":"crossref","unstructured":"Naggie S, Sulkowski M, Lalezari J, et\u00a0al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 21st Conference on Retroviruses and Opportunistic Infections (CROI)\u00a02014.","DOI":"10.1093\/ofid\/ofv133.1224"},{"key":"10.1016\/j.arcmed.2020.04.018_bib19","article-title":"Comprehensive Resistance Testing in Patients Who Relapsed after Treatment with Sofosbuvir (GS-7977)-Containing Regimens in Phase 2 Studies: 753","volume":"56","author":"Svarovskaia","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2020.04.018_bib20","article-title":"In\u00a0Vitro Pan-genotypic and Combination Activity of Sofosbuvir (GS-7977) in Stable Replicon Cell Lines: 1875","volume":"56","author":"Hebner","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2020.04.018_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gutjnl-2013-305771","article-title":"New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C","volume":"63","author":"Mari\u00f1o","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.arcmed.2020.04.018_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arcmed.2020.04.018_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short-and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2020.04.018_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arcmed.2020.04.018_bib25","doi-asserted-by":"crossref","first-page":"40920","DOI":"10.1038\/srep40920","article-title":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication","volume":"7","author":"Sacramento","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2020.04.018_bib26","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.celrep.2016.08.038","article-title":"Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia","volume":"16","author":"Onorati","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.arcmed.2020.04.018_bib27","first-page":"1","article-title":"Evaluation of Sofosbuvir (\u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine) as an inhibitor of Dengue virus replication","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2020.04.018_bib28","doi-asserted-by":"crossref","first-page":"e0007072","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in\u00a0vitro and in\u00a0vivo","volume":"13","author":"De Freitas","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.arcmed.2020.04.018_bib29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In\u00a0vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","author":"Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2020.04.018_bib30","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2020.04.018_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10863-006-9033-2","article-title":"Nucleoside diphosphate kinase A as a controller of AMP-kinase in airway epithelia","volume":"38","author":"Muimo","year":"2006","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.arcmed.2020.04.018_bib32","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1462-5822.2012.01825.x","article-title":"The cell biology of C hikungunya virus infection","volume":"14","author":"Tang","year":"2012","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.arcmed.2020.04.018_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","article-title":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","volume":"146","author":"Mumtaz","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arcmed.2020.04.018_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/labinvest.2017.137","article-title":"The NDPK\/NME superfamily: state of the art","volume":"98","author":"Boissan","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.arcmed.2020.04.018_bib35","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.bcp.2007.01.031","article-title":"The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue","volume":"73","author":"Mutch","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.arcmed.2020.04.018_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0006-2952(93)90373-5","article-title":"Nature and role of xenobiotic metabolizing esterases in rat liver, lung, skin and blood","volume":"45","author":"McCracken","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.arcmed.2020.04.018_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040206617738656","article-title":"Nucleoside diphosphate and triphosphate prodrugs\u2013An unsolvable task?","volume":"25","author":"Meier","year":"2017","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.arcmed.2020.04.018_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02587-17","article-title":"Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus","volume":"62","author":"Babusis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2020.04.018_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000research"},{"key":"10.1016\/j.arcmed.2020.04.018_bib40","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00399-10","article-title":"PSI-7851, a pronucleotide of \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication","volume":"54","author":"Lam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2020.04.018_bib41","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.dld.2014.09.026","article-title":"Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies","volume":"46","author":"Mangia","year":"2014","journal-title":"Dig Liver Dis"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920305518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920305518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:49:10Z","timestamp":1759261750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440920305518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0188440920305518"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.04.018","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered\/Approved Clinical Trial?","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}